Global Plasma Fractionation Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029
Plasma Fractionation is the process of fractionating whole blood or separating it into its component parts. This is typically done by centrifuging the blood.
Market Overview:The latest research study on the global Plasma Fractionation market finds that the global Plasma Fractionation market reached a value of USD 31298.28 million in 2022. It’s expected that the market will achieve USD 40847.95 million by 2028, exhibiting a CAGR of 4.54% during the forecast period.
Region Overview:From 2023-2028, North America is estimated to witness robust growth prospects.
Company Overview:CSL Behring is one of the major players operating in the Plasma Fractionation market, holding a share of 20.53% in 2019.
CSL Behring LLC, a biopharmaceutical company, engages in the research, development, manufacture, and marketing of protein-based therapies for the treatment of serious and rare conditions worldwide. It offers bleeding disorder, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing biotherapies. The company also operates a plasma collection network. Its therapies are indicated for the treatment of coagulation disorders, including hemophilia and von Willebrand disease; primary immune deficiencies; neurological conditions; inherited respiratory diseases; hereditary angioedema; cardiac surgery, organ transplantation, burn treatment, and hemolytic disease prevention in newborns; and chronic inflammatory demyelinating polyneuropathy in adults.
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses.
Segmentation Overview:Among different product types, Immune Globulin segment is anticipated to contribute the largest market share in 2028.
Application Overview:By application, the Immunology segment occupied the biggest share from 2018 to 2022.
Key Companies in the global Plasma Fractionation market covered in Chapter 3:Kedrion
Grifols
CSL Behring
BPL
Biotest
CBPO
Octapharma
RAAS
LFB Group
Takeda
Hualan Bio
In Chapter 4 and Chapter 14.2, on the basis of types, the Plasma Fractionation market from 2018 to 2029 is primarily split into:Albumin
Immune Globulin
Coagulation Factor
Others
In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Plasma Fractionation market from 2018 to 2029 covers:Immunology
Hematology
Other
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)